TY  - JOUR
TT  - Long term survival in a patient with recurrent metastatic Ewing sarcoma treated with irinotecan and temozolomide
AU  - Gelincik, Hakan
AU  - Küpeli, Serhan
PY  - 2016
DA  - December
Y2  - 2016
DO  - 10.17826/cutf.254553
JF  - Cukurova Medical Journal
JO  - Cukurova Med J
PB  - Çukurova Üniversitesi
WT  - DergiPark
SN  - 2602-3032
SP  - 811
EP  - 814
VL  - 41
IS  - 4
KW  - Ewing sarkom
KW  - irinotekan
KW  - temozolomid
N2  - Ewing sarcoma family of tumor is the second most common bone tumor in children and young adults, after osteosarcoma. Different chemotherapeutic regimens are used in treatment of relapsed/recurrent Ewing sarcoma. Promising results were achieved with combination of irinotecan and temozolomide. Our case was a 13-year-old female with relapsed Ewing sarcoma and after 12 cycles of irinotecan (20 mg/m2/10 days) and temozolomide (100mg/m2/5 days) treatment she had not any complaints, and her radiological lesions remained stable for 66 months. Irinotecan and temozolomide have been used successfully in treatment of relapsed/recurrent Ewing sarcoma, but there is a need for randomized prospective studies with larger patient groups for establishing the efficacy of this treatment protocol.
CR  - 1.	Ewing J. Classics in oncology. Diffuse endothelioma of bone. James Ewing. Proceedings of the New York Pathological Society, 1921. CA Cancer J Clin. 1972;22:95-8.
UR  - https://doi.org/10.17826/cutf.254553
L1  - https://dergipark.org.tr/tr/download/article-file/221322
ER  -